

# Andrew John Lees

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3581380/publications.pdf>

Version: 2024-02-01

745  
papers

90,376  
citations

240  
144  
h-index

443  
274  
g-index

766  
all docs

766  
docs citations

766  
times ranked

41443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 169-179.	1.9	17
2	Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 82-86.	1.5	2
3	REM Sleep Behavior Disorder and Visual Hallucinations in a Pathologically Confirmed Case of Corticobasal Degeneration. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 383-385.	1.5	1
4	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2022, 12, 77-91.	2.2	4
5	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	9.0	25
6	Patients' Postjudice of Tele-Neurology for Movement Disorders. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 446-451.	1.5	3
7	The motor prodromes of parkinson's disease: from bedside observation to large-scale application. <i>Journal of Neurology</i> , 2021, 268, 2099-2108.	3.6	27
8	Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson's disease. <i>Brain</i> , 2021, 144, 1787-1798.	7.6	44
9	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. <i>Brain</i> , 2021, 144, 1138-1151.	7.6	24
10	Improving estimation of Parkinson's disease risk – the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	5.3	13
11	Visual hallucinations. <i>Practical Neurology</i> , 2021, 21, 327-332.	1.1	5
12	Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson's Disease and Idiopathic Anosmia. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1901-1915.	2.8	6
13	Senior moments. <i>Brain</i> , 2021, 144, 2892-2895.	7.6	0
14	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	5.3	4
15	Bird watching on the asphalt. <i>Brain</i> , 2021, 144, 2-5.	7.6	6
16	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, , .	0.8	0
17	Dopamine devils. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 941-942.	0.8	0
18	Reply to "Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study." <i>Parkinsonism and Related Disorders</i> , 2021, 93, 31-32.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
20	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
21	Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease. Brain, 2020, 143, 3435-3448.	7.6	31
22	Telemedicine in Movement Disorders: Lessons du COVID-19. Movement Disorders, 2020, 35, 1893-1896.	3.9	24
23	Reply to: "A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders". Movement Disorders, 2020, 35, 1903-1904.	3.9	9
24	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
25	Hippocampal $\alpha$ -synuclein pathology correlates with memory impairment in multiple system atrophy. Brain, 2020, 143, 1798-1810.	7.6	31
26	<i>MYORG</i> -related disease is associated with central pontine calcifications and atypical parkinsonism. Neurology: Genetics, 2020, 6, e399.	1.9	13
27	Neuropathological Findings in Ephedrone Encephalopathy. Movement Disorders, 2020, 35, 1858-1863.	3.9	6
28	La Folie des Grands. Brain, 2020, 143, 2325-2328.	7.6	0
29	Brain iron deposition is linked with cognitive severity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 418-425.	1.9	121
30	Lithium: a slow burner. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 335-337.	1.9	2
31	Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction. Neurology, 2020, 94, e1525-e1538.	1.1	51
32	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson's Disease Patients. Journal of Parkinson's Disease, 2019, 9, 625-630.	2.8	13
33	Testing the reflexes. BMJ: British Medical Journal, 2019, 366, l4830.	2.3	3
34	The genetic and clinical-pathological profile of early-onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
35	Lower nucleus accumbens $\alpha$ -synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain, 2019, 142, 3580-3591.	7.6	17
36	Face-making: task-specific facial tensions and grimacing in musicians. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1180-1182.	1.9	1

#	ARTICLE	IF	CITATIONS
37	The spectrum of involuntary vocalizations in humans: A video atlas. <i>Movement Disorders</i> , 2019, 34, 1774-1791.	3.9	24
38	Listening with intent. <i>Practical Neurology</i> , 2019, 20, practneurol-2019-002307.	1.1	2
39	The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1288-1289.	1.9	3
40	The Bradykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 462-469.	1.5	23
41	Neuropathological progression of clinical Parkinson disease subtypes. <i>Nature Reviews Neurology</i> , 2019, 15, 361-361.	10.1	4
42	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 768-773.	1.9	29
43	Noticing in neurology. <i>Practical Neurology</i> , 2019, 19, 427-430.	1.1	4
44	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 555-561.	1.9	23
45	Will the Real James Parkinson Please Stand Up? Another Fake James Parkinson. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 269-270.	1.5	0
46	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 470.	9.0	205
47	Medical conferences: value for money?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 483-484.	1.9	6
48	Endemic atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2018, 388, 220-221.	0.6	2
49	“Flâneur neurologique in paris” A guide to pinpointing the houses of famous neurologists in the late XIX century. <i>Journal of Clinical Neuroscience</i> , 2018, 52, 32-36.	1.5	0
50	Phenotypes, genotypes, and the management of paroxysmal movement disorders. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 559-565.	2.1	31
51	Dopamine reuptake transporter “single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 478-482.	3.9	25
52	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinson's Disease</i> , 2018, 4, 2.	5.3	47
53	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.1	40
54	Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1121-1123.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Advice for those trying to find a cure for the shaking palsy. <i>Lancet Neurology</i> , The, 2018, 17, 27-28.	10.2	1
56	Apomorphine in the treatment of Parkinson's disease: a review. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 840-848.	0.8	31
57	Sir William Osler's "Influences"™ for the Successful Physician, A Reappraisal After 126 Years. <i>Archives of Medical Research</i> , 2018, 49, 418-420.	3.3	0
58	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. <i>Neurocase</i> , 2018, 24, 204-212.	0.6	19
59	Crime and Parkinson's: The jury is out. <i>Movement Disorders</i> , 2018, 33, 1092-1094.	3.9	7
60	Variation at the <i>TRIM11</i> locus modifies progressive supranuclear palsy phenotype. <i>Annals of Neurology</i> , 2018, 84, 485-496.	5.3	37
61	Small spiral, big mass. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1189-1190.	1.9	0
62	The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 519-522.	1.5	14
63	9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease. <i>NeuroImage: Clinical</i> , 2017, 13, 154-163.	2.7	49
64	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	3.9	59
65	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 65-71.	2.2	34
66	Blood-based NfL. <i>Neurology</i> , 2017, 88, 930-937.	1.1	369
67	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. <i>Acta Neuropathologica</i> , 2017, 133, 337-352.	7.7	193
68	Hemichorea as a Manifestation of Central Nervous System Chronic Graft-versus-Host Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 495-498.	1.5	1
69	Concerns Regarding Opicapone as Adjunct to Levodopa Therapy—Reply. <i>JAMA Neurology</i> , 2017, 74, 873.	9.0	1
70	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	1.9	19
71	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	2.8	11
72	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	9.0	146

#	ARTICLE	IF	CITATIONS
73	Reply: MRI findings of visual system alterations in Parkinson's disease. Brain, 2017, 140, e70-e70.	7.6	0
74	An essay on the shaking palsy. Brain, 2017, 140, 843-848.	7.6	15
75	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
76	William Burroughs: Sailor of the Soul. Journal of Psychoactive Drugs, 2017, 49, 385-392.	1.7	2
77	From Sgt. Pepper to Dreamachines: My Scientific Odyssey With William S. Burroughs. JAMA - Journal of the American Medical Association, 2017, 318, 2164.	7.4	0
78	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
79	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. Movement Disorders Clinical Practice, 2017, 4, 323-328.	1.5	33
80	2â€...Movement disorders â€“ the parkinsonâ€™s nÃ©vrose. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A1.2-A2.	1.9	0
81	Parkinsonâ€™s disease â€“ 200 years: the outstanding contribution of â€œOld Hubertâ€. Arquivos De Neuro-Psiquiatria, 2017, 75, 192-194.	0.8	2
82	Wilson's disease: the 60th anniversary of Walshe's article on treatment with penicillamine. Arquivos De Neuro-Psiquiatria, 2017, 75, 69-71.	0.8	4
83	Georges Simenon, Inspector Maigret and his relevance to the practice of Neurology. Arquivos De Neuro-Psiquiatria, 2017, 75, 189-191.	0.8	0
84	The relationship between the First World War and neurology: 100 years of â€œShell Shockâ€. Arquivos De Neuro-Psiquiatria, 2017, 75, 317-319.	0.8	6
85	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
86	James Parkinsonâ€™s Chimera: syndrome or disease?. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 190-195.	0.6	7
87	Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria. Revista De Psiquiatria Clinica, 2016, 43, 139-142.	0.6	5
88	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
89	Intrathoracic Malignancy Mimicking Axial Dystonia. Movement Disorders Clinical Practice, 2016, 3, 203-205.	1.5	1
90	Oral r(-)-11-o-valeryl-n<i>n</i>-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement Disorders, 2016, 31, 1381-1388.	3.9	7

#	ARTICLE	IF	CITATIONS
91	Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. Parkinsonism and Related Disorders, 2016, 27, 35-40.	2.2	40
92	MSA or SCA 17? A clinicopathological case update. Movement Disorders, 2016, 31, 1582-1584.	3.9	11
93	Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Current Treatment Options in Neurology, 2016, 18, 42.	1.8	63
94	Foreword. Parkinsonism and Related Disorders, 2016, 33, S1.	2.2	0
95	Visual dysfunction in Parkinson's disease. Brain, 2016, 139, 2827-2843.	7.6	320
96	Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse. Clinical Neurology and Neurosurgery, 2016, 147, 71-77.	1.4	9
97	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. Movement Disorders, 2016, 31, 668-675.	3.9	31
98	The prediagnostic phase of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 871-878.	1.9	122
99	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
100	<i>Banisteriopsis caapi</i>, a Forgotten Potential Therapy for Parkinson's Disease?. Movement Disorders Clinical Practice, 2016, 3, 19-26.	1.5	19
101	Jumping to conclusions in untreated patients with Parkinson's disease. Neuropsychologia, 2016, 85, 19-23.	1.6	19
102	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 633-641.	1.9	11
103	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
104	Hyposmia in SWEDD. Movement Disorders, 2015, 30, 1436-1437.	3.9	3
105	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	3.9	6
106	Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Chorea-acanthocytosis. Movement Disorders Clinical Practice, 2015, 2, 182-186.	1.5	4
107	A Brazilian Football Player Still on the Pitch After 10 Years of Parkinson's Disease with Severe Freezing of Gait. Movement Disorders Clinical Practice, 2015, 2, 43-44.	1.5	1
108	Minimal change multiple system atrophy: An aggressive variant?. Movement Disorders, 2015, 30, 960-967.	3.9	45

#	ARTICLE	IF	CITATIONS
109	Effects of Age and Cognition on a Cross-Cultural Paediatric Adaptation of the Sniffin' Sticks Identification Test. PLoS ONE, 2015, 10, e0131641.	2.5	16
110	The strange case of Dr William Gowers and Mr Sherlock Holmes. Brain, 2015, 138, 2103-2108.	7.6	8
111	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: Table A1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
112	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. Journal of Neurology, 2015, 262, 2653-2661.	3.6	41
113	The analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. Neurobiology of Aging, 2015, 36, 1221.e1-1221.e6.	3.1	39
114	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
115	Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17- $\beta$ hydroxysteroid dehydrogenase type 10. Cell Death and Differentiation, 2015, 22, 1563-1576.	11.2	33
116	Single versus multiple impulse control disorders in Parkinson's disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. Journal of Neurology, 2015, 262, 1504-1514.	3.6	41
117	The Story of 'Speed' from 'Cloud Nine' to Brain Gain. International Review of Neurobiology, 2015, 120, 1-7.	2.0	3
118	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	2.2	9
119	A geographical cluster of progressive supranuclear palsy in northern France. Neurology, 2015, 85, 1293-1300.	1.1	53
120	Four pioneers of L-Dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Movement Disorders, 2015, 30, 19-36.	3.9	76
121	How reliable are prodromal indicators of Parkinson disease?. Nature Reviews Neurology, 2015, 11, 5-6.	10.1	5
122	A Randomized Controlled Pilot Study to Evaluate a Technology Platform for the Assisted Living of People with Dementia and their Carers. Journal of Alzheimer's Disease, 2014, 41, 515-523.	2.6	88
123	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. PLoS ONE, 2014, 9, e96260.	2.5	52
124	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
125	Perceptual decision-making in patients with Parkinson's disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
126	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	1.9	90



#	ARTICLE	IF	CITATIONS
127	Bone health in Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1159-1166.	1.9	114
128	The case of the locked house. Neurology, 2014, 83, 661-664.	1.1	0
129	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1065-1075.	1.9	83
130	<scp>TDP</scp>â€43 pathology is present in most postâ€encephalitic parkinsonism brains. Neuropathology and Applied Neurobiology, 2014, 40, 654-657.	3.2	9
131	Alphaâ€synuclein mRNA expression in oligodendrocytes in MSA. Glia, 2014, 62, 964-970.	4.9	149
132	Safety and Efficacy of Tolcapone in the Long-term Use in Parkinson Disease. Clinical Neuropharmacology, 2014, 37, 1-5.	0.7	26
133	Progressive Parkinsonism, Balance Difficulties, and Supranuclear Gaze Palsy. JAMA Neurology, 2014, 71, 104.	9.0	21
134	Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. Acta Neuropathologica Communications, 2014, 2, 24.	5.2	21
135	The Significance of Î±-Synuclein, Amyloid-Î² and Tau Pathologies in Parkinson's Disease Progression and Related Dementia. Neurodegenerative Diseases, 2014, 13, 154-156.	1.4	83
136	Neuropathological features of multiple system atrophy with cognitive impairment. Movement Disorders, 2014, 29, 884-888.	3.9	38
137	Can stress trigger Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 878-881.	1.9	70
138	Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy. Neurobiology of Aging, 2014, 35, 1514.e1-1514.e12.	3.1	33
139	Late onset ataxia: MSAâ€ or SCA 17? A gene penetrance dilemma. Movement Disorders, 2014, 29, 36-38.	3.9	26
140	Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series. Journal of Neurology, 2013, 260, 1009-1013.	3.6	54
141	MM2 subtype of sporadic Creutzfeldt-Jakob disease may underlie the clinical presentation of progressive supranuclear palsy. Journal of Neurology, 2013, 260, 1031-1036.	3.6	22
142	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinsonâ€™s disease. Brain, 2013, 136, 400-411.	7.6	172
143	The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders, 2013, 28, 232-236.	3.9	121
144	Primary progressive aphasia with parkinsonism. Movement Disorders, 2013, 28, 741-746.	3.9	3

#	ARTICLE	IF	CITATIONS
145	Neuropathological findings in benign tremulous Parkinsonism. <i>Movement Disorders</i> , 2013, 28, 145-152.	3.9	68
146	The midbrain to pons ratio. <i>Neurology</i> , 2013, 80, 1856-1861.	1.1	153
147	Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. <i>Neuropathology and Applied Neurobiology</i> , 2013, 39, 121-131.	3.2	43
148	Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with <i>PRRT2</i> gene mutations. <i>Developmental Medicine and Child Neurology</i> , 2013, 55, 327-334.	2.1	39
149	Parkin Disease. <i>JAMA Neurology</i> , 2013, 70, 571.	9.0	119
150	The more cortical amyloid $\beta$ , the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?. <i>Movement Disorders</i> , 2013, 28, 263-264.	3.9	2
151	$\alpha$ -Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. <i>Acta Neuropathologica</i> , 2013, 125, 753-769.	7.7	369
152	Neurology and detective writing. <i>Practical Neurology</i> , 2013, 13, 372-376.	1.1	6
153	Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: Evidence from Parkinson's disease.. <i>Behavioral Neuroscience</i> , 2013, 127, 245-255.	1.2	40
154	Yorkshire's influence on the foundation of British Neurology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 6-9.	1.9	7
155	Pisa syndrome in Parkinson's disease: a mobile or fixed deformity?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1400-1403.	1.9	40
156	Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 883-887.	1.9	25
157	Shell shock at Queen Square: Lewis Yealland 100 years on. <i>Brain</i> , 2013, 136, 1976-1988.	7.6	24
158	Increased reflection impulsivity in patients with ephedrone-induced <i>Parkinsonism</i> . <i>Addiction</i> , 2013, 108, 771-779.	3.3	25
159	PARKIN DISEASE—A CLINICOPATHOLOGICAL ENTITY?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.35-e2.	1.9	1
160	Identification and Quantification of Oligodendrocyte Precursor Cells in Multiple System Atrophy, Progressive Supranuclear Palsy and <i>Parkinson's Disease</i> . <i>Brain Pathology</i> , 2013, 23, 263-273.	4.1	69
161	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 139-144.	2.8	39
162	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. <i>Movement Disorders</i> , 2013, 28, 408-408.	3.9	0

#	ARTICLE	IF	CITATIONS
163	Availability of olfactory bulb: experience from a British Brain Bank. Arquivos De Neuro-Psiquiatria, 2013, 71, 110-112.	0.8	1
164	Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series. Parkinson's Disease, 2013, 2013, 1-5.	1.1	29
165	Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239.	2.8	35
166	0854–Camptocormia: what is the cause?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.159-e1.	1.9	0
167	Familial camptocormia: from dystonia to myopathy: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 350-351.	1.9	5
168	DYT16: the original cases: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1012-1014.	1.9	21
169	120–An algorithm to identify individuals at high-risk of Parkinson's disease in the community. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.71-e1.	1.9	0
170	The relevance of the Lewy Body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 954-955.	1.9	17
171	118–The new Bradykinesia Akinesia Incoordination (BRAIN) test: an online test of upper limb movement. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.69-e1.	1.9	0
172	119–A pilot study of an algorithm designed to identify Parkinson's disease in the early, non-motor phase. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.70-e1.	1.9	0
173	William Gowers: the never completed third edition of the 'Bible of Neurology'. Brain, 2012, 135, 3178-3188.	7.6	7
174	Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. Journal of Neurochemistry, 2012, 123, 396-405.	3.9	64
175	Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?. Journal of Parkinson's Disease, 2012, 2, 7-18.	2.8	33
176	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.3	607
177	Opsoclonus Myoclonus Syndrome associated with GQ1b Antibodies. Movement Disorders, 2012, 27, 1615-1616.	3.9	10
178	Camptocormia: don't forget muscle disease in the movement disorder clinic. Journal of Neurology, 2012, 259, 1752-1754.	3.6	8
179	Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease. Journal of Neurology, 2012, 259, 2419-2423.	3.6	8
180	Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiology of Aging, 2012, 33, 814-823.	3.1	184

#	ARTICLE	IF	CITATIONS
181	Olfactory impairment in familial ataxias. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 970-974.	1.9	29
182	The clinical features of pathologically confirmed vascular Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1027-1029.	1.9	55
183	W R Gowers 1895: two unpublished post-graduate lectures. Brain, 2012, 135, 3165-3177.	7.6	2
184	Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. Movement Disorders, 2012, 27, 1230-1238.	3.9	158
185	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. Movement Disorders, 2012, 27, 1290-1294.	3.9	126
186	High resolution MR anatomy of the subthalamic nucleus: Imaging at 9.4T with histological validation. NeuroImage, 2012, 59, 2035-2044.	4.2	81
187	Letters from Dom Pedro II to professor Brown-SÃ©quard: imperial correspondence and neurophysiology. Arquivos De Neuro-Psiquiatria, 2012, 70, 633-636.	0.8	0
188	Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain, 2012, 135, 1141-1153.	7.6	191
189	Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Movement Disorders, 2012, 27, 1323-1323.	3.9	19
190	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2012, 27, 1754-1762.	3.9	163
191	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. Movement Disorders, 2012, 27, 1182-1185.	3.9	32
192	Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions?. Movement Disorders, 2012, 27, 1137-1145.	3.9	85
193	Multiple system atrophyâ€“parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2012, 27, 1186-1190.	3.9	164
194	Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Annals of Neurology, 2012, 71, 850-854.	5.3	103
195	The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathology and Applied Neurobiology, 2012, 38, 4-24.	3.2	218
196	Validation of the MDSâ€“UPDRS Part I for nonmotor symptoms in Parkinson's disease. Movement Disorders, 2012, 27, 79-83.	3.9	97
197	The new Bradykinesia Akinesia Incoordination (BRAIN) test: Preliminary data from an online test of upper limb movement. Movement Disorders, 2012, 27, 157-158.	3.9	12
198	Olfaction in pathologically proven patients with multiple system atrophy. Movement Disorders, 2012, 27, 327-328.	3.9	13

#	ARTICLE	IF	CITATIONS
199	Severe dysphagia as a presentation of Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 457-458.	3.9	24
200	Tricks of the trade. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 245-245.	0.8	1
201	Our Unforgettable Case of Malignant Motor Fluctuations in a Parkinson Patient. , 2012, , .		0
202	A Patient With Rapidly Progressive Dementia and Supranuclear Gaze Palsy: A Memorable Lesson on Prion Disorders. , 2012, , .		0
203	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011, 134, 969-978.	7.6	283
204	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 183-188.	0.6	42
205	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	21.4	502
206	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. <i>Molecular Genetics and Metabolism</i> , 2011, 103, 410-412.	1.1	40
207	Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 277-286.	2.8	106
208	Putaminal Upregulation of FosB/Î”FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia. <i>Journal of Parkinson's Disease</i> , 2011, 1, 347-357.	2.8	34
209	LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. <i>Neuropathology and Applied Neurobiology</i> , 2011, 37, 777-790.	3.2	44
210	Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. <i>Neuropsychologia</i> , 2011, 49, 103-107.	1.6	18
211	Novelty seeking behaviour in Parkinson's disease. <i>Neuropsychologia</i> , 2011, 49, 2483-2488.	1.6	66
212	Pathological gambling in Parkinson's diseaseâ€”a review of the literature. <i>Movement Disorders</i> , 2011, 26, 1976-1984.	3.9	40
213	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. <i>Acta Neuropathologica</i> , 2011, 122, 415-428.	7.7	67
214	Transportin1: a marker of FTL-D-FUS. <i>Acta Neuropathologica</i> , 2011, 122, 591-600.	7.7	58
215	Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: Clinicopathological case. <i>Movement Disorders</i> , 2011, 26, 424-429.	3.9	1
216	The effect of drug treatment on neurogenesis in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 45-50.	3.9	38

#	ARTICLE	IF	CITATIONS
217	Use of smell test identification in Parkinson's disease in Mexico: A matched case-control study. Movement Disorders, 2011, 26, 173-176.	3.9	22
218	A film of patients with movement disorders made in Queen Square, London in the Mid-1920s by Samuel Alexander Kinnier Wilson. Movement Disorders, 2011, 26, 2453-2459.	3.9	11
219	Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	3.9	4
220	An intragenic duplication in guanosine triphosphate cyclohydrolase-1 gene in a dopa-responsive dystonia family. Movement Disorders, 2011, 26, 905-909.	3.9	12
221	Up with the lark. Neurology, 2011, 77, 310-311.	1.1	3
222	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain, 2011, 134, 2548-2564.	7.6	76
223	Î±-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18666-18671.	7.1	154
224	Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 620-622.	1.9	27
225	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	7.6	497
226	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics, 2011, 20, 345-353.	2.9	202
227	Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain, 2011, 134, 2339-2357.	7.6	116
228	Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain, 2011, 134, 3299-3309.	7.6	132
229	Does levodopa accelerate the pathologic process in Parkinson disease brain?. Neurology, 2011, 77, 1420-1426.	1.1	59
230	Applying a new version of the Brazilian-Portuguese UPSIT smell test in Brazil. Arquivos De Neuro-Psiquiatria, 2010, 68, 700-705.	0.8	42
231	Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of Neurology, 2010, 68, 619-628.	5.3	221
232	Reckless generosity in Parkinson's disease. Movement Disorders, 2010, 25, 221-223.	3.9	16
233	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	3.9	43
234	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2010, 25, 1077-1081.	3.9	106

#	ARTICLE	IF	CITATIONS
235	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. Movement Disorders, 2010, 25, 867-876.	3.9	48
236	Impulsiveâ€compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Movement Disorders, 2010, 25, 638-642.	3.9	33
237	<i>ATP13A2</i> mutations (PARK9) cause neurodegeneration with brain iron accumulation. Movement Disorders, 2010, 25, 979-984.	3.9	163
238	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Movement Disorders, 2010, 25, 896-905.	3.9	63
239	What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsyâ€parkinsonism (PSPâ€P)? . Movement Disorders, 2010, 25, 357-362.	3.9	106
240	Excessive hoarding in Parkinson's disease. Movement Disorders, 2010, 25, 1026-1033.	3.9	50
241	Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. Movement Disorders, 2010, 25, 560-569.	3.9	223
242	Earlyâ€onset Lâ€dopaâ€responsive parkinsonism with pyramidal signs due to <i>ATP13A2, PLA2G6, FBXO7</i> and <i>spatacsin</i> mutations. Movement Disorders, 2010, 25, 1791-1800.	3.9	287
243	Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model. Movement Disorders, 2010, 25, 2508-2515.	3.9	117
244	Olfactory heterogeneity in <i>LRRK2</i> related Parkinsonism. Movement Disorders, 2010, 25, 2879-2883.	3.9	33
245	What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Movement Disorders, 2010, 25, 2493-2500.	3.9	405
246	Hypoxic ischemia and proteasome dysfunction alter tau isoform ratio by inhibiting exon 10 splicing. Journal of Neurochemistry, 2010, 114, 160-170.	3.9	10
247	A Huntington's disease phenocopy characterized by pallido-nigro-lusian degeneration with brain iron accumulation and p62-positive glial inclusions. Neuropathology and Applied Neurobiology, 2010, 36, 551-557.	3.2	11
248	POC08 A case of central and peripheral vestibular vestibular failure. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e36-e37.	1.9	0
249	Olfactory function in Parkinson's disease in ON versus OFF states. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1293-1295.	1.9	12
250	PATH54 Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e22-e22.	1.9	0
251	Intact Reward Learning but Elevated Delay Discounting in Parkinson's Disease Patients With Impulsive-Compulsive Spectrum Behaviors. Neuropsychopharmacology, 2010, 35, 2155-2164.	5.4	159
252	Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1223-1228.	1.9	91



#	ARTICLE	IF	CITATIONS
253	NONCOMPRESSIVE MYELOPATHY ASSOCIATED WITH VIOLENT AXIAL TICS OF TOURETTE SYNDROME. <i>Neurology</i> , 2010, 74, 697-698.	1.1	29
254	Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. <i>Brain</i> , 2010, 133, 727-745.	7.6	171
255	Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. <i>Brain</i> , 2010, 133, 1755-1762.	7.6	349
256	POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, e57-e57.	1.9	1
257	Preface. <i>Neuroimaging Clinics of North America</i> , 2010, 20, xiii.	1.0	1
258	Does corticobasal degeneration exist? A clinicopathological re-evaluation. <i>Brain</i> , 2010, 133, 2045-2057.	7.6	414
259	In vivo assessment of brain monoamine systems in parkin gene carriers: A PET study. <i>Experimental Neurology</i> , 2010, 222, 120-124.	4.1	25
260	How Can Neuroimaging Help in the Diagnosis of Movement Disorders?. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 111-123.	1.0	7
261	Expanding the links between Brazilian and British neurology. <i>Arquivos De Neuro-Psiquiatria</i> , 2010, 68, 493-494.	0.8	2
262	Konstantin N. Tretiakoff in Brazil a historical perspective and discussion of his contribution to brazilian neuroscience. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 322-327.	0.8	5
263	Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 267-272.	1.9	14
264	Hyposmia in pure autonomic failure. <i>Neurology</i> , 2009, 72, 1677-1681.	1.1	49
265	A clinico-pathological study of subtypes in Parkinson's disease. <i>Brain</i> , 2009, 132, 2947-2957.	7.6	385
266	Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 744-748.	1.9	65
267	Differential DJ-1 gene expression in Parkinson's disease. <i>Neurobiology of Disease</i> , 2009, 36, 393-400.	4.4	42
268	Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. <i>Lancet Neurology</i> , The, 2009, 8, 270-279.	10.2	642
269	Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremorâ€Ataxia syndrome. <i>Movement Disorders</i> , 2009, 24, 1245-1247.	3.9	15
270	The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. <i>Movement Disorders</i> , 2009, 24, 1144-1153.	3.9	34



#	ARTICLE	IF	CITATIONS
271	Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka. <i>Movement Disorders</i> , 2009, 24, 1229-1233.	3.9	38
272	Nigrostriatal dysfunction in homozygous and heterozygous <i>&lt;i&gt;parkin&lt;/i&gt;</i> gene carriers: An <sup>18</sup> F-dopa PET progression study. <i>Movement Disorders</i> , 2009, 24, 2260-2266.	3.9	44
273	A validation exercise on the new consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 2272-2276.	3.9	100
274	Can olfactory bulb biopsy be justified for the diagnosis of Parkinson's disease? Comments on 'Olfactory bulb $\alpha$ -synucleinopathy has high specificity and sensitivity for Lewy body disorders'. <i>Acta Neuropathologica</i> , 2009, 117, 213-214.	7.7	23
275	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. <i>Acta Neuropathologica</i> , 2009, 118, 359-369.	7.7	30
276	How do patients with parkinsonism present? A clinicopathological study. <i>Internal Medicine Journal</i> , 2009, 39, 7-12.	0.8	33
277	Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies. <i>Journal of Neuroscience Methods</i> , 2009, 180, 34-42.	2.5	23
278	Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1477-1482.	3.1	48
279	Dopamine dysregulation syndrome, impulse control disorders and punning after deep brain stimulation surgery for Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1148-1152.	1.5	220
280	Regional differences in the severity of Lewy body pathology across the olfactory cortex. <i>Neuroscience Letters</i> , 2009, 453, 77-80.	2.1	110
281	Characterisation of a novel NR4A2 mutation in Parkinson's disease brain. <i>Neuroscience Letters</i> , 2009, 457, 75-79.	2.1	36
282	Concomitant progressive supranuclear palsy and multiple system atrophy: More than a simple twist of fate?. <i>Neuroscience Letters</i> , 2009, 467, 208-211.	2.1	19
283	Dopamine Dysregulation Syndrome. <i>CNS Drugs</i> , 2009, 23, 157-170.	5.9	203
284	Parkinson's disease. <i>Lancet</i> , The, 2009, 373, 2055-2066.	13.7	1,835
285	Degeneration in Different Parkinsonian Syndromes Relates to Astrocyte Type and Astrocyte Protein Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1073-1083.	1.7	173
286	The Parkinson chimera. <i>Neurology</i> , 2009, 72, S2-11.	1.1	61
287	Cortical $\alpha$ -synuclein load is associated with amyloid- $\beta$ plaque burden in a subset of Parkinson's disease patients. <i>Acta Neuropathologica</i> , 2008, 115, 417-425.	7.7	146
288	The auditory startle response in parkinsonism may reveal the extent but not type of pathology. <i>Journal of Neurology</i> , 2008, 255, 628-632.	3.6	25

#	ARTICLE	IF	CITATIONS
289	Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study. <i>Movement Disorders</i> , 2008, 23, 101-106.	3.9	228
290	The black stuff and Konstantin Nikolaevich Tretiakoff. <i>Movement Disorders</i> , 2008, 23, 777-783.	3.9	55
291	The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. <i>Movement Disorders</i> , 2008, 23, 2328-2334.	3.9	122
292	Normal dopamine transporter single photonâ€ emission CT scan in corticobasal degeneration. <i>Movement Disorders</i> , 2008, 23, 2424-2426.	3.9	42
293	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2008, 7, 583-590.	10.2	1,340
294	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. <i>Nature Medicine</i> , 2008, 14, 501-503.	30.7	1,595
295	Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease. <i>CNS Neuroscience &amp; Therapeutics</i> , 2008, 14, 83-93.	4.0	24
296	Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: Contrast with other dementias. <i>Journal of Chemical Neuroanatomy</i> , 2008, 35, 268-274.	2.1	6
297	Unified Parkinson's Disease Rating Scale (UPDRS) part I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 586-587.	2.2	9
298	J. Clifford Richardson and 50 years of progressive supranuclear palsy. <i>Neurology</i> , 2008, 70, 566-573.	1.1	50
299	Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. <i>Brain</i> , 2008, 131, 1362-1372.	7.6	355
300	Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 492-505.	3.2	28
301	Parkinson's disease with Onuf's nucleus involvement mimicking multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 232-234.	1.9	21
302	Neuropathology of primary adult-onset dystonia. <i>Neurology</i> , 2008, 70, 695-699.	1.1	42
303	Sensorimotor reorganization by proprioceptive training in musician's dystonia and writer's cramp. <i>Neurology</i> , 2008, 70, 304-315.	1.1	72
304	Hyposmia in G2019S LRRK2-related parkinsonism. <i>Neurology</i> , 2008, 71, 1021-1026.	1.1	82
305	The Neuro-Behavioural Syndrome of Brainstem Disease. <i>Neurocase</i> , 2008, 13, 452-465.	0.6	16
306	Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. <i>Neurology</i> , 2008, 71, 474-480.	1.1	246

#	ARTICLE	IF	CITATIONS
307	A new look at James Parkinson's <i>Essay on the Shaking Palsy</i>. Neurology, 2007, 69, 482-485.	1.1	58
308	The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 571-575.	1.9	12
309	Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain, 2007, 130, 2123-2128.	7.6	172
310	Quantifying the impact of dyskinesias in PD. Neurology, 2007, 69, 555-563.	1.1	40
311	Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology, 2007, 68, 1553-1554.	1.1	32
312	Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 944-948.	1.9	37
313	Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 652-655.	1.9	91
314	Muscarinic Receptors in the Thalamus in Progressive Supranuclear Palsy and Other Neurodegenerative Disorders. Journal of Neuropathology and Experimental Neurology, 2007, 66, 399-404.	1.7	13
315	Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain, 2007, 130, 1566-1576.	7.6	364
316	Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple system atrophy from progressive supranuclear palsy. Movement Disorders, 2007, 22, 68-74.	3.9	132
317	Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets. Movement Disorders, 2007, 22, 715-719.	3.9	3
318	Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Movement Disorders, 2007, 22, 895-897.	3.9	25
319	[ <sup>123</sup> I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Movement Disorders, 2007, 22, 1278-1285.	3.9	100
320	Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Movement Disorders, 2007, 22, 1229-1238.	3.9	206
321	Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Movement Disorders, 2007, 22, 1594-1600.	3.9	24
322	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders, 2007, 22, 1757-1763.	3.9	246
323	Pure akinesia with gait freezing: A third clinical phenotype of progressive supranuclear palsy. Movement Disorders, 2007, 22, 2235-2241.	3.9	216
324	The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. European Journal of Neuroscience, 2007, 26, 417-423.	2.6	34

#	ARTICLE	IF	CITATIONS
325	MRI derived brain atrophy in PSP and MSA-P. Journal of Neurology, 2007, 254, 478-481.	3.6	45
326	Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 468-473.	1.9	145
327	Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Experimental Neurology, 2006, 199, 465-478.	4.1	43
328	Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. Journal of Neurochemistry, 2006, 98, 156-169.	3.9	146
329	Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nature Genetics, 2006, 38, 1032-1037.	21.4	344
330	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. Acta Neuropathologica, 2006, 112, 439-449.	7.7	41
331	Amyotrophic lateral sclerosis with dementia: an autopsy case showing many Bunina bodies, tau-positive neuronal and astrocytic plaque-like pathologies, and pallido-nigral degeneration. Acta Neuropathologica, 2006, 112, 633-645.	7.7	28
332	Antiparkinsonian drugs and visual hallucinations – Authors' response. Lancet Neurology, The, 2006, 5, 19-20.	10.2	2
333	Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. Movement Disorders, 2006, 21, 118-119.	3.9	36
334	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. Movement Disorders, 2006, 21, 299-305.	3.9	18
335	Did Gustav Mahler have Sydenham's chorea?. Movement Disorders, 2006, 21, 289-292.	3.9	4
336	Upregulation of dopamine D <sub>2</sub> receptors in dopaminergic drug-naïve patients with parkin gene mutations. Movement Disorders, 2006, 21, 783-788.	3.9	34
337	Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Movement Disorders, 2006, 21, 989-996.	3.9	119
338	Melanized nigral neuronal numbers in Nigerian and British individuals. Movement Disorders, 2006, 21, 1239-1241.	3.9	13
339	Holmes tremor: Application of modern neuroimaging techniques. Movement Disorders, 2006, 21, 2260-2262.	3.9	49
340	Case of DYT1 dystonia triggered by bite from a moray. Movement Disorders, 2006, 21, 1536-1537.	3.9	8
341	NR4A2 genetic variation in sporadic Parkinson's disease: A genome-wide approach. Movement Disorders, 2006, 21, 1960-1963.	3.9	15
342	Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Movement Disorders, 2006, 21, 1737-1741.	3.9	61

#	ARTICLE	IF	CITATIONS
343	Punding and dyskinesias. <i>Movement Disorders</i> , 2006, 21, 2214-2217.	3.9	76
344	A genetic cluster of early onset Parkinson's disease in a Colombian population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 885-889.	1.7	20
345	UCHL-1 is not a Parkinson's disease susceptibility gene. <i>Annals of Neurology</i> , 2006, 59, 627-633.	5.3	123
346	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , 2006, 59, 852-858.	5.3	435
347	PINK1 protein in normal human brain and Parkinson's disease. <i>Brain</i> , 2006, 129, 1720-1731.	7.6	291
348	Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. <i>Brain</i> , 2006, 129, 1040-1049.	7.6	192
349	Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. <i>Neurology</i> , 2006, 67, 1612-1617.	1.1	173
350	The $\alpha$ -synuclein gene in multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 464-467.	1.9	45
351	Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. <i>Lancet Neurology</i> , The, 2005, 4, 605-610.	10.2	294
352	Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 133B, 120-123.	1.7	18
353	Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. <i>Movement Disorders</i> , 2005, 20, 151-157.	3.9	262
354	Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. <i>Movement Disorders</i> , 2005, 20, 479-484.	3.9	32
355	Clinical grand round: A rapidly progressive pyramidal and extrapyramidal syndrome with a supranuclear gaze palsy. <i>Movement Disorders</i> , 2005, 20, 826-831.	3.9	5
356	Lesion of the dorsorostral midbrain sparing the nigrostriatal tract mimics axial rigidity seen in progressive supranuclear palsy. <i>Movement Disorders</i> , 2005, 20, 1071-1075.	3.9	4
357	Kufor Rakeb Disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. <i>Movement Disorders</i> , 2005, 20, 1264-1271.	3.9	177
358	Spinocerebellar ataxia type 17: Extension of phenotype with putaminal rim hyperintensity on magnetic resonance imaging. <i>Movement Disorders</i> , 2005, 20, 1521-1523.	3.9	40
359	Parkinson's disease: A broken nosology. <i>Movement Disorders</i> , 2005, 20, S2-S4.	3.9	18
360	Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis. <i>Movement Disorders</i> , 2005, 20, S114-S118.	3.9	29

#	ARTICLE	IF	CITATIONS
361	Neuronal intranuclear inclusion disease: Report on a case originally diagnosed as dopa-responsive dystonia with Lewy bodies. <i>Movement Disorders</i> , 2005, 20, 1345-1349.	3.9	46
362	Reply: Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. <i>Movement Disorders</i> , 2005, 20, 1086-1087.	3.9	0
363	Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). <i>Movement Disorders</i> , 2005, 20, 1115-1119.	3.9	45
364	UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. <i>Movement Disorders</i> , 2005, 20, 1338-1343.	3.9	17
365	Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. <i>Movement Disorders</i> , 2005, 20, 1425-1430.	3.9	64
366	Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. <i>Journal of Medical Genetics</i> , 2005, 42, 837-846.	3.2	225
367	Long duration asymmetric postural tremor in the development of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 9-9.	1.9	9
368	Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single <i>parkin</i> mutation. <i>Neurology</i> , 2005, 64, 134-136.	1.1	132
369	Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1594-1596.	1.9	15
370	Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. <i>Neurology</i> , 2005, 65, 1570-1574.	1.1	233
371	Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 77, 317-321.	1.9	162
372	Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. <i>Neurocase</i> , 2005, 11, 274-282.	0.6	68
373	Pathophysiological differences between musician's dystonia and writer's cramp. <i>Brain</i> , 2005, 128, 918-931.	7.6	190
374	The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. <i>Brain</i> , 2005, 128, 1855-1860.	7.6	172
375	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. <i>Brain</i> , 2005, 128, 2786-2796.	7.6	315
376	A common LRRK2 mutation in idiopathic Parkinson's disease. <i>Lancet, The</i> , 2005, 365, 415-416.	13.7	391
377	The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. <i>Human Molecular Genetics</i> , 2005, 14, 2399-2404.	2.9	205
378	Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. <i>Brain</i> , 2005, 128, 1247-1258.	7.6	743

#	ARTICLE	IF	CITATIONS
379	Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. <i>Neurology</i> , 2005, 64, 675-679.	1.1	168
380	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. <i>Neurobiology of Disease</i> , 2005, 20, 401-411.	4.4	40
381	Development, characterisation and epitope mapping of novel monoclonal antibodies for DJ-1 (PARK7) protein. <i>Neuroscience Letters</i> , 2005, 383, 225-230.	2.1	11
382	Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1749-1752.	1.9	111
383	Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1772-1775.	1.9	14
384	Tau gene and Parkinson's disease: a case-control study and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 962-965.	1.9	112
385	Genome-Wide Analysis of the Parkinsonism-Dementia Complex of Guam. <i>Archives of Neurology</i> , 2004, 61, 1889-97.	4.5	44
386	The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. <i>Brain</i> , 2004, 127, 420-430.	7.6	404
387	Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. <i>Brain</i> , 2004, 127, 2441-2451.	7.6	54
388	The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. <i>Brain</i> , 2004, 127, 2657-2671.	7.6	493
389	Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. <i>Brain</i> , 2004, 128, 116-125.	7.6	148
390	Parkinsonism due to Kernohan notch: Clinical, structural, and functional imaging correlates. <i>Neurology</i> , 2004, 62, 2333-2334.	1.1	15
391	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. <i>Brain</i> , 2004, 127, 1332-1342.	7.6	104
392	Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. <i>Acta Psychiatrica Scandinavica</i> , 2004, 109, 140-146.	4.5	69
393	A functional polymorphism regulating dopamine $\beta$ -hydroxylase influences against Parkinson's disease. <i>Annals of Neurology</i> , 2004, 55, 443-446.	5.3	59
394	The gene responsible for PARK6 Parkinson's disease, PINK1, does not influence common forms of parkinsonism. <i>Annals of Neurology</i> , 2004, 56, 329-335.	5.3	38
395	Dementia in dementia with Lewy bodies may not be attributable to Alzheimer pathology. <i>Annals of Neurology</i> , 2004, 56, 604-604.	5.3	0
396	Diagnostic considerations in juvenile parkinsonism. <i>Movement Disorders</i> , 2004, 19, 123-135.	3.9	62



#	ARTICLE	IF	CITATIONS
397	Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disorders, 2004, 19, 181-189.	3.9	190
398	Alteration in $\alpha$ -synuclein mRNA expression in Parkinson's disease. Movement Disorders, 2004, 19, 162-170.	3.9	111
399	Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. Movement Disorders, 2004, 19, 397-405.	3.9	488
400	New therapeutic indications for botulinum toxins. Movement Disorders, 2004, 19, S157-S161.	3.9	49
401	Patterns of EMG-EMG coherence in limb dystonia. Movement Disorders, 2004, 19, 758-769.	3.9	60
402	Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Movement Disorders, 2004, 19, 630-640.	3.9	332
403	Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies. Movement Disorders, 2004, 19, 1190-1196.	3.9	39
404	Natural history and syndromic associations of orthostatic tremor: A review of 41 patients. Movement Disorders, 2004, 19, 788-795.	3.9	224
405	L-dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. Movement Disorders, 2004, 19, 1232-1236.	3.9	23
406	Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Movement Disorders, 2004, 19, 1006-1011.	3.9	15
407	Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1672-1677.	1.9	201
408	Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain, 2004, 127, 21-33.	7.6	300
409	P4-035 Melanized nigral neurons in Caucasians and Africans. Neurobiology of Aging, 2004, 25, S482.	3.1	0
410	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Molecular Brain Research, 2004, 121, 95-101.	2.3	20
411	Failure in heat-shock protein expression in response to UBB+1 protein in progressive supranuclear palsy in humans. Neuroscience Letters, 2004, 359, 94-98.	2.1	5
412	Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology, 2004, 63, 638-643.	1.1	65
413	Olfaction and Parkinson's syndromes: its role in differential diagnosis. Current Opinion in Neurology, 2004, 17, 417-423.	3.6	137
414	Dopamine dysregulation syndrome in Parkinson's disease. Current Opinion in Neurology, 2004, 17, 393-398.	3.6	218



#	ARTICLE	IF	CITATIONS
415	Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. <i>Neurology</i> , 2004, 62, 1224-1226.	1.1	127
416	Anti-basal ganglia antibodies in patients with atypical dystonia and tics. <i>Neurology</i> , 2004, 63, 156-158.	1.1	36
417	Quality of life in patients with orthostatic tremor. <i>Journal of Neurology</i> , 2003, 250, 212-215.	3.6	35
418	Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. <i>Lancet Neurology</i> , The, 2003, 2, 595-604.	10.2	278
419	CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome?. <i>Journal of Neuroimmunology</i> , 2003, 136, 149-153.	2.3	87
420	Cerebral amyloid angiopathy and motor neurone disease presenting with a progressive supranuclear palsy-like syndrome. <i>Movement Disorders</i> , 2003, 18, 331-336.	3.9	12
421	Lack of association between progressive supranuclear palsy and arterial hypertension: A clinicopathological study. <i>Movement Disorders</i> , 2003, 18, 694-697.	3.9	21
422	Influence of target size on vertical gaze palsy in a pathologically proven case of progressive supranuclear palsy. <i>Movement Disorders</i> , 2003, 18, 818-822.	3.9	10
423	Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders. <i>Movement Disorders</i> , 2003, 18, 1123-1131.	3.9	26
424	Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings. <i>Movement Disorders</i> , 2003, 18, 28-33.	3.9	59
425	Dopamine transporter imaging. <i>Movement Disorders</i> , 2003, 18, S1-S2.	3.9	0
426	Health-related quality of life in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2003, 18, 1464-1469.	3.9	68
427	[123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. <i>Annals of Neurology</i> , 2003, 53, 489-496.	5.3	83
428	Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. <i>Annals of Neurology</i> , 2003, 54, 235-238.	5.3	204
429	The role of pathogenic <i>LRRK2</i> mutations in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 283-286.	5.3	362
430	Clinical features and natural history of progressive supranuclear palsy. <i>Neurology</i> , 2003, 60, 910-916.	1.1	264
431	Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. <i>Neurology</i> , 2003, 61, 102-104.	1.1	86
432	Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. <i>Neurochemistry International</i> , 2003, 43, 129-135.	3.8	96

#	ARTICLE	IF	CITATIONS
433	Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 602-607.	1.9	150
434	Lewy body cortical involvement may not always predict dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 852-856.	1.9	176
435	Tremor in Parkinson's disease and serotonergic dysfunction. Neurology, 2003, 60, 601-605.	1.1	277
436	Parkin disease: a phenotypic study of a large case series. Brain, 2003, 126, 1279-1292.	7.6	427
437	Strong association of the <i>Saitohin</i> gene Q7 variant with progressive supranuclear palsy. Neurology, 2003, 61, 407-409.	1.1	27
438	Alzheimer's associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression. Journal of Neurochemistry, 2003, 86, 394-404.	3.9	78
439	Reporting Clinical Trials: Full Access to All of the Data. Archives of Neurology, 2002, 59, 27.	4.5	5
440	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 388-390.	1.9	17
441	Reporting clinical trials: full access to all the data. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 143-143.	1.9	0
442	[ <sup>123</sup> I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. Neurology, 2002, 59, 1974-1976.	1.1	33
443	Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology, 2002, 59, 227-231.	1.1	276
444	Reporting clinical trials. Neurology, 2002, 58, 347-348.	1.1	5
445	Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?. Neurology, 2002, 59, 1486-1491.	1.1	121
446	Drugs for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 607-610.	1.9	24
447	Analysis of <i>tau</i> haplotypes in Pick's disease. Neurology, 2002, 59, 443-445.	1.1	50
448	The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 2002, 125, 861-870.	7.6	1,108
449	The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Letters, 2002, 531, 538-542.	2.8	52
450	Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism and Related Disorders, 2002, 9, 39-54.	2.2	34

#	ARTICLE	IF	CITATIONS
451	The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2002, 330, 201-203.	2.1	39
452	The Slow Axonal Transport of the Microtubule-Associated Protein Tau and the Transport Rates of Different Isoforms and Mutants in Cultured Neurons. <i>Journal of Neuroscience</i> , 2002, 22, 6394-6400.	3.6	69
453	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. <i>Brain</i> , 2002, 125, 2248-2256.	7.6	141
454	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. <i>Brain</i> , 2002, 125, 969-975.	7.6	80
455	Bilaterally coherent tremor resembling enhanced physiological tremor: Report of three cases. <i>Movement Disorders</i> , 2002, 17, 387-391.	3.9	16
456	Reporting clinical trials: Full access to all the data. <i>Movement Disorders</i> , 2002, 17, 3-4.	3.9	5
457	Adult-onset tic disorders. <i>Movement Disorders</i> , 2002, 17, 735-740.	3.9	56
458	EMG-EMG coherence in writer's cramp. <i>Movement Disorders</i> , 2002, 17, 1011-1016.	3.9	17
459	Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. <i>Movement Disorders</i> , 2002, 17, 1235-1241.	3.9	210
460	Reporting clinical trials: full access to all the data. <i>Journal of Neurology</i> , 2002, 249, 638-639.	3.6	0
461	The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. <i>Brain</i> , 2001, 124, 1438-1449.	7.6	226
462	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. <i>Neuroscience Letters</i> , 2001, 311, 145-148.	2.1	49
463	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. <i>Neuroscience Letters</i> , 2001, 312, 118-120.	2.1	26
464	Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. <i>Neurology</i> , 2001, 57, 1497-1499.	1.1	729
465	A clinical and pathological study of motor neurone disease on Guam. <i>Brain</i> , 2001, 124, 2215-2222.	7.6	39
466	Familial Progressive supranuclear Palsy. <i>Archives of Neurology</i> , 2001, 58, 1846.	4.5	42
467	Treatment of dystonic clenched fist with botulinum toxin. <i>Movement Disorders</i> , 2001, 16, 907-913.	3.9	104
468	Attention and cognition in bradykinetic-rigid syndromes: An event-related potential study. <i>Annals of Neurology</i> , 2001, 50, 567-573.	5.3	39

#	ARTICLE	IF	CITATIONS
469	Unusual tremor associated with a posterolateral thalamic lesion in a drummer. <i>Movement Disorders</i> , 2001, 16, 174-176.	3.9	0
470	High dose naltrexone for dyskinesias induced by levodopa. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 554-556.	1.9	48
471	Polymyography Combined with Time-Locked Video Recording (Video EMG) for Presurgical Assessment of Patients with Cervical Dystonia. <i>European Neurology</i> , 2001, 45, 222-228.	1.4	10
472	Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. <i>Brain</i> , 2001, 124, 769-783.	7.6	82
473	Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations. <i>Brain</i> , 2001, 124, 331-340.	7.6	92
474	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001, 56, 1702-1706.	1.1	392
475	Ten-year follow-up of three different initial treatments in de-novo PD. <i>Neurology</i> , 2001, 57, 1687-1694.	1.1	141
476	SPECT imaging of the dopamine transporter in juvenile-onset dystonia. <i>Neurology</i> , 2001, 56, 266-267.	1.1	39
477	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. <i>Archives of Neurology</i> , 2001, 58, 1813.	4.5	114
478	Nonparkinsonian Tremors. <i>Clinical Neuropharmacology</i> , 2000, 23, 233-238.	0.7	16
479	Sign language tics in a prelingually deaf man. <i>Movement Disorders</i> , 2000, 15, 318-320.	3.9	19
480	Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 336-337.	3.9	62
481	Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. <i>Movement Disorders</i> , 2000, 15, 503-510.	3.9	650
482	Movement disorders in 30 patients with tuberculous meningitis. <i>Movement Disorders</i> , 2000, 15, 561-569.	3.9	75
483	Reply. <i>Movement Disorders</i> , 2000, 15, 587-588.	3.9	2
484	Neuronal intranuclear inclusion disease and juvenile Parkinsonism. <i>Movement Disorders</i> , 2000, 15, 990-995.	3.9	46
485	Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. <i>Brain</i> , 2000, 123, 1422-1430.	7.6	48
486	Botulinum toxin A as treatment for drooling saliva in PD. <i>Neurology</i> , 2000, 55, 606-607.	1.1	31

#	ARTICLE	IF	CITATIONS
487	Low-dose olanzapine for levodopa induced dyskinesias. <i>Neurology</i> , 2000, 55, 795-799.	1.1	72
488	Multiple system atrophy/progressive supranuclear palsy: $\alpha$ -Synuclein, synphilin, tau, and <i>APOE</i> .	1.1	82
489	Differentiation of atypical parkinsonian syndromes with routine MRI. <i>Neurology</i> , 2000, 54, 697-697.	1.1	401
490	An ambulatory dyskinesia monitor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 196-201.	1.9	65
491	Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 423-428.	1.9	514
492	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 665-667.	1.9	103
493	Parkinson's syndrome after closed head injury: a single case report. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 380-385.	1.9	37
494	Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 442-446.	1.9	53
495	Yawning in Parkinson's disease. <i>Neurology</i> , 1999, 52, 428-428.	1.1	11
496	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). <i>Postgraduate Medical Journal</i> , 1999, 75, 579-584.	1.8	35
497	Bradykinesia akinesia inco-ordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 624-629.	1.9	84
498	Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 511-517.	1.9	28
499	Mortality in DATATOP. <i>Annals of Neurology</i> , 1999, 45, 138-139.	5.3	10
500	Mutation in the tau exon 10 splice site region in familial frontotemporal dementia. <i>Annals of Neurology</i> , 1999, 45, 270-271.	5.3	43
501	Selegiline-induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal. <i>Movement Disorders</i> , 1999, 14, 246-251.	3.9	54
502	GPI Firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine. <i>Movement Disorders</i> , 1999, 14, 481-483.	3.9	31
503	Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. <i>Movement Disorders</i> , 1999, 14, 530-532.	3.9	21
504	Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics. <i>Movement Disorders</i> , 1999, 14, 731-736.	3.9	40

#	ARTICLE	IF	CITATIONS
505	Atypical parkinsonism in the French West Indies. Lancet, The, 1999, 354, 1474.	13.7	4
506	Use of apomorphine in Parkinson's disease. British Journal of Hospital Medicine, 1999, 60, 816-820.	0.2	22
507	Parkinsonism following electrical injury to the hand. Movement Disorders, 1998, 13, 600-602.	3.9	9
508	Acute movement disorders with bilateral basal ganglia lesions in uremia. Movement Disorders, 1998, 13, 952-957.	3.9	61
509	Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Molecular Brain Research, 1998, 63, 62-71.	2.3	107
510	Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology, 1998, 50, 573.	1.1	7
511	Clinical usefulness of magnetic resonance imaging in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 65-71.	1.9	236
512	Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 573-576.	1.9	204
513	Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 577-580.	1.9	57
514	A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain, 1998, 121, 59-75.	7.6	120
515	Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ: British Medical Journal, 1998, 316, 1191-1196.	2.3	86
516	Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species. Journal of Neurochemistry, 1998, 71, 2112-2122.	3.9	326
517	Down's syndrome and Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 289-289.	1.9	13
518	In vivo studies on striatal dopamine D <sub>1</sub> and D <sub>2</sub> site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology, 1997, 49, 717-723.	1.1	159
519	Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 228-234.	1.9	95
520	The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology, 1997, 49, 1570-1576.	1.1	183
521	Dopaminergic function in patients with posttraumatic parkinsonism: An <sup>18</sup> F-dopa PET study. Neurology, 1997, 49, 183-189.	1.1	33
522	Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain, 1997, 120, 75-90.	7.6	149

#	ARTICLE	IF	CITATIONS
523	Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. Neuroscience Letters, 1997, 221, 161-164.	2.1	34
524	Dopaminergic function in familial Parkinson's disease: A clinical and <sup>18</sup> F-dopa positron emission tomography study. Annals of Neurology, 1997, 41, 222-229.	5.3	140
525	Selegiline and mortality in Parkinson's disease: Another view. Annals of Neurology, 1997, 41, 282-283.	5.3	10
526	Torticollis due to disinhibition of the vestibulo-collic reflex in a patient with Steele-Richardson-Olszewski syndrome. Movement Disorders, 1997, 12, 328-336.	3.9	31
527	Proton magnetic resonance spectroscopy in steele-richardson-olszewski syndrome. Movement Disorders, 1997, 12, 767-771.	3.9	88
528	Cerebellar axial postural tremor. Movement Disorders, 1997, 12, 977-984.	3.9	37
529	Parkinsonism associated with acute intracranial hematomas: An [18F]dopa positron-emission tomography study. Movement Disorders, 1997, 12, 1035-1038.	3.9	36
530	Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8-hydroxyguanine Levels in Substantia Nigra. Journal of Neurochemistry, 1997, 69, 1196-1203.	3.9	715
531	A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease. Journal of Neurochemistry, 1997, 69, 1326-1329.	3.9	483
532	Nocturnal and respiratory disturbances in Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	1.8	31
533	Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 1996, 75, 389-406.	2.3	22
534	Ropinirole in the Treatment of Levodopa-Induced Motor Fluctuations in Patients with Parkinson's Disease. Clinical Neuropharmacology, 1996, 19, 234-245.	0.7	103
535	Botulinum Toxin in the Treatment of Writer's Cramp. Clinical Neuropharmacology, 1996, 19, 314-320.	0.7	30
536	Treatment of nonoccupational limb and trunk dystonia with botulinum toxin. Movement Disorders, 1996, 11, 377-383.	3.9	18
537	A neuromyotonic process in a transposed latissimus dorsi muscle stemming from radiotherapy and peripheral surgery. Movement Disorders, 1996, 11, 449-451.	3.9	19
538	Amyloid $\beta$ -peptide and the dementia of Parkinson's disease. Movement Disorders, 1996, 11, 647-653.	3.9	45
539	Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair. Journal of Neurology, 1996, 243, 667-670.	3.6	7
540	Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 634-637.	1.9	78

#	ARTICLE	IF	CITATIONS
541	Possible clinical overlap between postencephalitic parkinsonism and progressive supranuclear palsy.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 589-590.	1.9	9
542	The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. Advances in Neurology, 1996, 69, 393-8.	0.8	5
543	The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq1 1 0.784314 rgBT /Overlock 10	7.6	298
544	Familial progressive supranuclear palsy. Brain, 1995, 118, 1095-1103.	7.6	98
545	Hereditary juvenile parkinsonism with pyramidal signs and mental retardation. European Journal of Neurology, 1995, 2, 23-26.	3.3	7
546	Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. Movement Disorders, 1995, 10, 179-187.	3.9	100
547	Auctioneer's jaw: A case of occupational oromandibular hemidystonia. Movement Disorders, 1995, 10, 508-509.	3.9	92
548	Stuttering, tic-like facial movements and behavioural disorders. Journal of Neurology, 1995, 243, 105-106.	3.6	5
549	A case of progressive subcortical gliosis associated with deposition of abnormal prion protein (PrP). Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 759-760.	1.9	11
550	Magnetic resonance spectroscopic study of parkinsonism related to boxing.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 688-691.	1.9	51
551	MATTERS ARISING: Davie et al reply.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 562-562.	1.9	0
552	Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome. Brain, 1995, 118, 951-958.	7.6	75
553	Some Specific Clinical Features Differentiate Multiple System Atrophy (Striatonigral Variety) From Parkinson's Disease. Archives of Neurology, 1995, 52, 294-298.	4.5	170
554	Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 601-607.	1.9	39
555	Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Molecular Brain Research, 1995, 28, 311-318.	2.3	304
556	Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience, 1995, 66, 361-376.	2.3	112
557	The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease. Journal of Clinical Psychopharmacology, 1995, 15, 51S-59S.	1.4	37
558	Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ: British Medical Journal, 1995, 311, 1602-1607.	2.3	312



#	ARTICLE	IF	CITATIONS
559	Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1444-1444.	1.9	2
560	HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 180-185.	1.9	32
561	The nature of apraxia in corticobasal degeneration.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 455-459.	1.9	134
562	Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1249-1251.	1.9	19
563	Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 186-189.	1.9	80
564	Micrographia associated with a parietal lobe lesion in multiple sclerosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 739-741.	1.9	22
565	MATTERS ARISING: Leiguarda et al reply.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1549-1549.	1.9	1
566	Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 430-434.	1.9	37
567	PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 688-692.	1.9	96
568	Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Movement Disorders, 1994, 9, 92-97.	3.9	400
569	Subcortical neurofibrillary degeneration presenting as Steeleâ€Richardsonâ€Olzewski and other related syndromes: A review of 90 pathologically verified cases. Movement Disorders, 1994, 9, 381-389.	3.9	49
570	Unusual focal dyskinesias: The ears, the shoulders, the back, and the abdomen. Movement Disorders, 1994, 9, 531-538.	3.9	104
571	Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology, 1994, 35, 38-44.	5.3	333
572	Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 1994, 36, 348-355.	5.3	1,052
573	Glutathione-related enzymes in brain in Parkinson's disease. Annals of Neurology, 1994, 36, 356-361.	5.3	287
574	Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 79-88.	1.9	241
575	Intense oxidative DNA damage promoted by L-DOPA and its metabolites implications for neurodegenerative disease. FEBS Letters, 1994, 353, 246-250.	2.8	249
576	Incidental Lewy body disease in black Africans. Lancet, The, 1994, 344, 882-883.	13.7	25

#	ARTICLE	IF	CITATIONS
577	Nitric oxide synthase mRNA expression in human subthalamic nucleus, striatum and globus pallidus: implications for basal ganglia function. <i>Molecular Brain Research</i> , 1994, 22, 329-332.	2.3	29
578	Levodopa Substitution: The Gold Standard. <i>Clinical Neuropharmacology</i> , 1994, 17, S1-S6.	0.7	22
579	The auditory startle response in progressive supranuclear palsy. <i>Journal of Neural Transmission Supplementum</i> , 1994, 42, 43-50.	0.5	11
580	Torticollis after electrocution. <i>Movement Disorders</i> , 1993, 8, 117-118.	3.9	21
581	Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years. <i>Movement Disorders</i> , 1993, 8, 165-170.	3.9	220
582	Inverse masticatory muscle activity due to syringobulbia. <i>Movement Disorders</i> , 1993, 8, 359-360.	3.9	4
583	Dopamine agonists in Parkinson's disease: a look at apomorphine. <i>Fundamental and Clinical Pharmacology</i> , 1993, 7, 121-128.	1.9	113
584	The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 771-775.	1.9	9
585	Effects of Treatment on Airway Dynamics and Respiratory Muscle Strength in Parkinson's Disease. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1576-1580.	2.9	79
586	The metabolic effects of limbic leucotomy in Gilles de la Tourette syndrome.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 1016-1019.	1.9	30
587	A Clinicopathologic Study of 100 Cases of Parkinson's Disease. <i>Archives of Neurology</i> , 1993, 50, 140-148.	4.5	881
588	Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. <i>Brain</i> , 1993, 116, 281-302.	7.6	119
589	Diagnosis of PD. <i>Neurology</i> , 1993, 43, 1630-1630.	1.1	4
590	Parkinson's Disease Society Brain Bank, London: overview and research. <i>Journal of Neural Transmission Supplementum</i> , 1993, 39, 165-72.	0.5	347
591	Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 1024-1026.	1.9	41
592	Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 413-413.	1.9	14
593	THE AUDITORY STARTLE RESPONSE IN THE STEELE-RICHARDSON-OLSEWSKI SYNDROME AND PARKINSON'S DISEASE. <i>Brain</i> , 1992, 115, 1181-1192.	7.6	115
594	The dopaminergic response in multiple system atrophy.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 1009-1013.	1.9	152

#	ARTICLE	IF	CITATIONS
595	Botulinum toxin.. BMJ: British Medical Journal, 1992, 305, 1169-1170.	2.3	19
596	What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142.	1.1	1,139
597	Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 181-184.	1.9	9,027
598	Hallucinations and parkinsonian Motor Fluctuations. Behavioural Neurology, 1992, 5, 83-86.	2.1	14
599	Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin. Journal of Neurology, 1992, 239, 1-4.	3.6	63
600	When did Ray Kennedy's Parkinson's disease begin?. Movement Disorders, 1992, 7, 110-116.	3.9	92
601	Temporary deterioration in Parkinsonian signs after modest alcohol intake. Movement Disorders, 1992, 7, 284-285.	3.9	4
602	Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report. Movement Disorders, 1992, 7, 355-358.	3.9	73
603	Letters to the Editor. Movement Disorders, 1992, 7, 387-391.	3.9	11
604	Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with <sup>11</sup> C-raclopride and positron emission tomography. Annals of Neurology, 1992, 31, 184-192.	5.3	423
605	?-tocopherol levels in brain are not altered in Parkinson's disease. Annals of Neurology, 1992, 32, 591-593.	5.3	73
606	The identification of presymptomatic parkinsonism: Clinical and { <sup>18</sup> F}dopa positron emission tomography studies in an irish kindred. Annals of Neurology, 1992, 32, 609-617.	5.3	75
607	Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Annals of Neurology, 1992, 32, 749-757.	5.3	426
608	Rectal apomorphine in Parkinson's disease. Lancet, The, 1991, 337, 118.	13.7	39
609	ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE METALS IN PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA. Brain, 1991, 114, 1953-1975.	7.6	948
610	The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease. Clinical Neuropharmacology, 1991, 14, 209-213.	0.7	23
611	Sublingual Apomorphine in the Treatment of Parkinson's Disease Complicated by Motor Fluctuations. Clinical Neuropharmacology, 1991, 14, 556-561.	0.7	24
612	Intranasal apomorphine in Parkinson's disease. Neurology, 1991, 41, 761-762.	1.1	46

#	ARTICLE	IF	CITATIONS
613	AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY. <i>Brain</i> , 1991, 114, 2283-2301.	7.6	3,002
614	Selegiline hydrochloride and cognition. <i>Acta Neurologica Scandinavica</i> , 1991, 84, 91-94.	2.1	26
615	Dopa-responsive dystonia: [18F]dopa positron emission tomography. <i>Annals of Neurology</i> , 1991, 30, 24-30.	5.3	100
616	Neuronal inclusions of Parkinson's disease. <i>Movement Disorders</i> , 1991, 6, 2-11.	3.9	88
617	Writer's cramp: Treatment with botulinum toxin injections. <i>Movement Disorders</i> , 1991, 6, 55-59.	3.9	98
618	Paroxysmal dystonic head tremor. <i>Movement Disorders</i> , 1991, 6, 85-86.	3.9	58
619	Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. <i>Movement Disorders</i> , 1991, 6, 342-346.	3.9	9
620	Complex stereotypies after right putaminal infarction: A case report. <i>Movement Disorders</i> , 1991, 6, 358-361.	3.9	52
621	Case 2, 1991: Unusual tremor, myoclonus, and a limping gait. <i>Movement Disorders</i> , 1991, 6, 371-375.	3.9	4
622	OBSessional SLOWNESS. <i>Brain</i> , 1991, 114, 2191-2202.	7.6	135
623	Diffuse Lewy body disease presenting with a supranuclear gaze palsy.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 159-161.	1.9	71
624	Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 388-396.	1.9	465
625	A case of progressive encephalomyelitis with rigidity and positive antiglutamic acid decarboxylase antibodies [corrected]. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 449-451.	1.9	34
626	Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 373-373.	1.9	9
627	Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. <i>Neurology</i> , 1991, 41, 1723-1723.	1.1	110
628	Buspirone in the treatment of levodopa induced dyskinesias.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 376-377.	1.9	69
629	Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 972-975.	1.9	19
630	The motor response to sequential apomorphine in parkinsonian fluctuations.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 358-360.	1.9	34

#	ARTICLE	IF	CITATIONS
631	Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 938-938.	1.9	9
632	The Effect of Sleep on the Dyskinetic Movements of Parkinson's Disease, Gilles de la Tourette Syndrome, Huntington's Disease, and Torsion Dystonia. Archives of Neurology, 1991, 48, 210-214.	4.5	133
633	New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology, 1991, 41, 820-820.	1.1	46
634	Apomorphine in the Diagnosis and Treatment of Parkinsonian Tremor. Clinical Neuropharmacology, 1990, 13, 312-317.	0.7	25
635	Management of Gilles de la Tourette Syndrome Using Sulpiride. Clinical Neuropharmacology, 1990, 13, 229-235.	0.7	84
636	STRIATONIGRAL DEGENERATION. Brain, 1990, 113, 1823-1842.	7.6	289
637	Decreased Ferritin Levels in Brain in Parkinson's Disease. Journal of Neurochemistry, 1990, 55, 16-20.	3.9	244
638	Differing patterns of striatal18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Annals of Neurology, 1990, 28, 547-555.	5.3	641
639	Diaphragmatic flutter, the moving umbilicus syndrome, and ?belly dancer's? dyskinesia. Movement Disorders, 1990, 5, 15-22.	3.9	114
640	Exaggerated startle reflexes in an elderly woman. Movement Disorders, 1990, 5, 167-169.	3.9	11
641	Tics. Behavioural Neurology, 1990, 3, 99-108.	2.1	3
642	Subcutaneous apomorphine in the treatment of Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 96-101.	1.9	285
643	Comparison of motor response to apomorphine and levodopa in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 1004-1007.	1.9	92
644	Diurnal differences in response to oral levodopa.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 948-950.	1.9	22
645	Marijuana for parkinsonian tremor.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 436-436.	1.9	72
646	The treatment of Gilles de la Tourette syndrome by limbic leucotomy.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 691-694.	1.9	70
647	Neurological deterioration in young adults with phenylketonuria. Lancet, The, 1990, 336, 602-605.	13.7	201
648	Botulinum toxin treatment in spasmodic torticollis.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 640-643.	1.9	165

#	ARTICLE	IF	CITATIONS
649	Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet, The, 1990, 336, 32-34.	13.7	164
650	Tics. Behavioural Neurology, 1990, 3, 99-108.	2.1	1
651	The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 193-200.	1.9	91
652	The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1063-1067.	1.9	49
653	The relationship between eye-winking tics, frequent eye-blinking and blepharospasm.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 477-480.	1.9	36
654	A pathological study of the association between Lewy body disease and Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 701-708.	1.9	64
655	Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 718-723.	1.9	104
656	Anal Sphincter Dysfunction in Parkinson's Disease. Archives of Neurology, 1989, 46, 1061-1064.	4.5	156
657	Sublingual apomorphine and Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1440-1440.	1.9	35
658	Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 72-76.	1.9	182
659	Abnormalities of the blink reflex in Gilles de la Tourette syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 895-898.	1.9	86
660	New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurologica Scandinavica, 1989, 80, 139-145.	2.1	17
661	THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE. Neuropathology and Applied Neurobiology, 1989, 15, 27-44.	3.2	279
662	Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Movement Disorders, 1989, 4, 47-52.	3.9	61
663	The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Movement Disorders, 1989, 4, 53-74.	3.9	24
664	Prevalence of lewy bodies in alzheimer's disease. Annals of Neurology, 1989, 26, 691-692.	5.3	14
665	Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease. Journal of Neurochemistry, 1989, 52, 1830-1836.	3.9	1,054
666	Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature. Psychological Medicine, 1989, 19, 611-625.	4.5	173

#	ARTICLE	IF	CITATIONS
667	A Double-Blind, Controlled Study of High-Dose L-Deprenyl in the Treatment of Parkinson's Disease. Clinical Neuropharmacology, 1989, 12, 448.	0.7	13
668	Lewy body disease. Neurology, 1989, 39, 878.	1.1	4
669	Tendency to late recurrence following rheumatic chorea. Neurology, 1989, 39, 999-999.	1.1	9
670	Alzheimer pathology in Parkinson's disease. Neurology, 1989, 39, 874.	1.1	1
671	Dystonia in parkinson's disease: Clinical and pharmacological features. Annals of Neurology, 1988, 23, 73-78.	5.3	158
672	Pathological report of four patients presenting with cranial dystonias. Movement Disorders, 1988, 3, 211-221.	3.9	81
673	The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 745-752.	1.9	2,935
674	ROLE OF SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN VOIDING DYSFUNCTION. Lancet, The, 1988, 332, 1451-1453.	13.7	114
675	SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS. Lancet, The, 1988, 331, 403-406.	13.7	278
676	A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1224-1227.	1.9	36
677	Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 850-854.	1.9	137
678	Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon?. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1503-1507.	1.9	140
679	A comparison of clinical and pathological features of young and old onset Parkinson's disease. Neurology, 1988, 38, 1402-1402.	1.1	340
680	The Nighttime Problems of Parkinson's Disease. Clinical Neuropharmacology, 1988, 11, 512-519.	0.7	382
681	STEELE-RICHARDSON-OLSZEWSKI SYNDROME. Brain, 1988, 111, 615-630.	7.6	133
682	The Psychopathology of the Gilles de la Tourette Syndrome. British Journal of Psychiatry, 1988, 152, 383-390.	2.8	257
683	Late Progression of Post-Encephalitic Parkinson's Syndrome. Canadian Journal of Neurological Sciences, 1988, 15, 135-138.	0.5	53
684	CLINICAL AND PATHOLOGICAL FEATURES OF DIFFUSE CORTICAL LEWY BODY DISEASE (LEWY BODY) Tj ETQq0 0 0 rgBT /Overlock 10 T	7.6	243



#	ARTICLE	IF	CITATIONS
685	Cigarette smoking, Parkinson's disease and ulcerative colitis.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 635-635.	1.9	10
686	Mesulergine and pergolide in previously untreated Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 482-484.	1.9	7
687	ENCEPHALITIS LETHARGICA. Brain, 1987, 110, 19-33.	7.6	164
688	The Pharmacology of Foot Dystonia in Parkinsonism. Clinical Neuropharmacology, 1987, 10, 47-56.	0.7	25
689	BRADYPHRENIA IN PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE ILLNESS. Brain, 1987, 110, 761-776.	7.6	226
690	INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN. Lancet, The, 1987, 330, 1219-1220.	13.7	488
691	The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathologica, 1987, 73, 195-201.	7.7	36
692	The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit onâ€œff fluctuations.. British Journal of Clinical Pharmacology, 1986, 22, 429-436.	2.4	76
693	PAROXYSMAL HEMIGLOSSAL TWISTING. Lancet, The, 1986, 328, 812-813.	13.7	13
694	The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. Neuroscience Letters, 1986, 65, 79-83.	2.1	38
695	Treatment of Motor Fluctuations in Parkinson's Disease with an Oral Sustained-Release Preparation of L-Dopa. Clinical Neuropharmacology, 1986, 9, 430-439.	0.7	53
696	The clinical phenomenon of akathisia.. Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 861-866.	1.9	75
697	Lowâ€œdose Lâ€œdopa therapy in Parkinson's disease. Neurology, 1986, 36, 1528-1528.	1.1	147
698	The clinical features and natural history of the Steeleâ€œRichardsonâ€œOlszewski syndrome (progressive) Tj ETQq0 0 0 rgBT /Overlock 10 7	1.1	206
699	Georges Gilles de la Tourette. The man and his times. Revue Neurologique, 1986, 142, 808-16.	1.5	22
700	The Controversial Role of Bromocriptine in Parkinson's Disease. Clinical Neuropharmacology, 1985, 8, 150-155.	0.7	10
701	The pre-morbid personality of patients with Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 97-100.	1.9	115
702	Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 1234-1239.	1.9	98



#	ARTICLE	IF	CITATIONS
703	Giant cell arteritis with spinal cord infarction and basilar artery thrombosis.. Journal of Neurology, Neurosurgery and Psychiatry, 1985, 48, 945-948.	1.9	49
704	Reversible coma in Wernicke's encephalopathy. Postgraduate Medical Journal, 1985, 61, 607-610.	1.8	13
705	Persistent rheumatic chorea. Neurology, 1985, 35, 101-101.	1.1	17
706	Methysergide in progressive supranuclear palsy. Neurology, 1985, 35, 936-936.	1.1	14
707	A clinical study of Gilles de la Tourette syndrome in the United Kingdom.. Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 1-8.	1.9	154
708	ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE. Brain, 1984, 107, 487-506.	7.6	276
709	Kinesigenic foot dystonia as a presenting feature of Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 885-885.	1.9	34
710	Remission in spasmodic torticollis.. Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 1236-1237.	1.9	159
711	Chorea in digoxin toxicity.. Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 419-419.	1.9	17
712	Autosomal recessive late onset multisystem disorder with cerebellar cortical atrophy at necropsy: report of a family.. Journal of Neurology, Neurosurgery and Psychiatry, 1984, 47, 853-856.	1.9	5
713	HEMIDYSTONIA RELIEVED BY NICOTINE. Lancet, The, 1984, 324, 871.	13.7	16
714	Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Acta Neurologica Scandinavica, 1983, 68, 113-116.	2.1	22
715	Platelet phenolsulphotransferase activity in Parkinson's disease. Journal of Neural Transmission, 1983, 57, 95-102.	2.8	10
716	COGNITIVE DEFICITS IN THE EARLY STAGES OF PARKINSON'S DISEASE. Brain, 1983, 106, 257-270.	7.6	818
717	Levodopa induced chorea in Meige syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 286-286.	1.9	0
718	Sustained levodopa therapy in tardive dyskinesia.. Journal of Neurology, Neurosurgery and Psychiatry, 1983, 46, 685-685.	1.9	4
719	Histocompatibility antigens and post-encephalitic Parkinsonism.. Journal of Neurology, Neurosurgery and Psychiatry, 1982, 45, 1060-1061.	1.9	10
720	The contribution of amphetamine metabolites of (?)-deprenyl to its antiparkinsonian properties. Journal of Neural Transmission, 1982, 54, 105-110.	2.8	51

#	ARTICLE	IF	CITATIONS
721	PERGOLIDE AND LISURIDE FOR LEVODOPA-INDUCED OSCILLATIONS. Lancet, The, 1981, 318, 577.	13.7	20
722	Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1981, 44, 1020-1023.	1.9	130
723	The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 54	1.9	42
724	Differential antagonism by neuroleptics of backward-walking and other behaviours caused by amphetamine at high dosage. Neuropharmacology, 1980, 19, 549-553.	4.1	19
725	BROMOCRIPTINE IN TREATMENT OF LEVODOPA-INDUCED END-OF-DOSE DYSTONIA. Lancet, The, 1980, 316, 215-216.	13.7	11
726	Tiapride in levodopa-induced involuntary movements.. Journal of Neurology, Neurosurgery and Psychiatry, 1979, 42, 380-383.	1.9	27
727	Spinal internuncial neurones in progressive encephalomyelitis with rigidity.. Journal of Neurology, Neurosurgery and Psychiatry, 1979, 42, 773-785.	1.9	84
728	BACKWARD WALKING AND CIRCLING: BEHAVIOURAL RESPONSES INDUCED BY DRUG TREATMENTS WHICH CAUSE SIMULTANEOUS RELEASE OF CATECHOLAMINES AND 5â€¢HYDROXYTRYPTAMINE. British Journal of Pharmacology, 1979, 66, 573-579.	5.4	62
729	NEUROSYPHILIS TODAY. Lancet, The, 1979, 313, 90-93.	13.7	44
730	Serotonergic involvement in behavioural responses to amphetamine at high dosage. Neuropharmacology, 1979, 18, 153-158.	4.1	57
731	Niacin Depletion in Parkinsonian Patients Treated with L-dopa, Benserazide and Carbidopa. Clinical Science, 1979, 56, 89-93.	4.3	39
732	Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?. Psychopharmacology, 1978, 57, 33-38.	3.1	247
733	Recent observations on the clinical pharmacology of (-)deprenyl. Journal of Neural Transmission, 1978, 43, 245-251.	2.8	76
734	Endocrine aspects of bromocriptine therapy in Parkinsonism. Journal of Neural Transmission, 1978, 43, 153-160.	2.8	14
735	Deprenyl is metabolized to methamphetamine and amphetamine in man.. British Journal of Clinical Pharmacology, 1978, 6, 542-544.	2.4	270
736	Bromocriptine in Parkinsonism. Archives of Neurology, 1978, 35, 503.	4.5	52
737	Baclofen in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1978, 41, 707-708.	1.9	41
738	Problems in the Diagnosis of Progressive Supranuclear Palsy (Steele â€” Richardson â€” Olszewski) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 54	0.5	54

#	ARTICLE	IF	CITATIONS
739	Bromocriptine in presenile dementia.. BMJ: British Medical Journal, 1978, 1, 1052-1053.	2.3	10
740	HALLUCINATIONS AFTER WITHDRAWAL OF BACLOFEN. Lancet, The, 1977, 309, 858.	13.7	34
741	BROMOCRIPTINE AND THYROID-STIMULATING-HORMONE SECRETION. Lancet, The, 1977, 310, 1128-1129.	13.7	3
742	DEPRENYL IN PARKINSON'S DISEASE. Lancet, The, 1977, 310, 791-795.	13.7	264
743	GROWTH-HORMONE RESPONSE TO BROMOCRIPTINE IN PARKINSONISM. Lancet, The, 1976, 307, 194.	13.7	10
744	Anterior tibial compartment syndrome following prolonged tetany. Journal of Neurology, Neurosurgery and Psychiatry, 1976, 39, 406-408.	1.9	9
745	Le Bal des Folles. Brain, 0, , .	7.6	0